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Post-hoc analyses of the Rotavirus Efficacy and Safety Trial (REST) were conducted to determine whether the pentavalent
rotavirus vaccine (RV5) confers early protection against rotavirus gastroenteritis (RVGE) before completion of the 3-dose
regimen. To evaluate the efficacy of RV5 between doses in reducing the rates of RVGE-related hospitalizations and
emergency department (ED) visits in infants who ultimately received all 3 doses of RV5/placebo, events occurring from
two weeks after the first and second doses to receipt of the subsequent dose (Analysis A) and events occurring from two
weeks after the first and second doses to two weeks after the subsequent dose (Analysis B) were analyzed. In Analysis A,
RV5 reduced the rates of combined hospitalizations and ED visits for G1–G4 RVGE or RVGE regardless of serotype between
doses 1 and 2 by 100% [95% confidence interval (CI): 72–100%] or 82% (95% CI: 39–97%), respectively, and between doses
2 and 3, RV5 reduced the rates of combined hospitalizations and ED visits for G1–G4 RVGE or RVGE regardless of serotype
by 91% (95% CI: 63–99%) or 84% (95% CI: 54–96%), respectively. Similar rate reductions were observed in Analysis B.
These data suggest that RV5 provides a high level of protection between doses against hospitalizations and ED visits for
RVGE starting as early as 14 days after the first dose.

Introduction
Over the years, several vaccines have been developed to protect children from rotaviruses, the leading cause of severe diarrhea in children less than 5 years of age. Two rotavirus vaccines
have now been licensed in many parts of the world: a pentavalent live human-bovine reassortant vaccine (RotaTeq, rotavirus
vaccine, live, oral, pentavalent; Merck, Whitehouse Station,
New Jersey, US; designated RV5 by the Advisory Committee
on Immunization Practices [ACIP]1) and a live, attenuated
G1P1A[8] human rotavirus vaccine (Rotarix, GlaxoSmithKline
Biologicals, Rixensart, Belgium; designated RV1 by the ACIP1).
The efficacy of RV5 following receipt of the recommended
3-dose series was evaluated in the Rotavirus Efficacy and Safety
Trial (REST) in 2 ways: (1) reduction in the rates of rotavirus

gastroenteritis (RVGE) hospitalizations and emergency department (ED) visits; and (2) prevention of RVGE cases.2,3 In REST,
the rate of RVGE hospitalizations and ED visits caused by G1–
G4 rotaviruses was reduced by 95% (95% confidence interval
[CI]: 91–97%) by RV5 through up to 2 years after completion
of the vaccination schedule. The rate of RVGE hospitalizations
and ED visits caused by rotaviruses of any serotype was also
reduced by 95% (95% CI: 92–97%) by RV5. In REST, enrollment occurred year round and the per-protocol analyses were
based on follow-up beginning 14 days after the third dose. In this
paper, post-hoc analyses of REST were conducted to determine
whether RV5 confers protection to infants before completion of
the 3-dose regimen. These analyses may be of particular interest
to health care professionals immunizing infants during, or just
prior to, the rotavirus season.
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Table 1. Rate reduction in RVGE-related health care encounters (hospitalizations and ED visits) between vaccine dosesa attributable to G1–G4
rotavirus
G1–G4 RVGEb

Interval (N)

Health care encounter

Vaccine

Placebo

Efficacy (%)

95% CI (%)

Counts (n)/evaluable (n)
Analysis Ac

Doses 1 to 2 (58,851)

Doses 2 to 3 (59,061)

Analysis Bd

Doses 1 to 2 (58,851)

Doses 2 to 3 (59,019)

Hospitalizations

0/29,417

6/29,434

100

15–100

ED visits

0/29,417

9/29,434

100

49–100

Combined hospital and ED visits

0/29,417

15/29,434

100

72–100

Hospitalizations

0/29,496

10/29,565

100

55–100
25–98

ED visits

2/29,496

12/29,565

83

Combined hospital and ED visits

2/29,496

22/29,565

91

63–99

Hospitalizations

0/29,413

12/29,438

100

64–100

ED visits

0/29,413

17/29,438

100

76–100

Combined hospital and ED visits

0/29,413

29/29,438

100

87–100

Hospitalizations

0/29,473

18/29,546

100

77–100

ED visits

3/29,473

16/29,546

81

34–97

Combined hospital and ED visits

3/29,473

34/29,546

91

72–98

N, number of evaluable infants who received 3 doses of vaccine or placebo; RVGE, rotavirus gastroenteritis; CI, confidence interval; ED, emergency
department. aGiven that the interval between doses was to be 4–10 weeks, the range of follow up was 14–56 days per infant in Analysis A and 14–69
days per infant in Analysis B. bThe most common rotavirus serotype identified was G1, followed by a few samples that contained G2, G4, and G3 rotavirus strains. Between doses 1 and 2 among placebo recipients, the distribution of the rotavirus serotypes in the total number (n = 29) of RVGE-related
health care encounters in Analysis B, which also includes the 15 health care encounters in Analysis A, was G1 (n = 22), G2 (n = 4), G3 (n = 1), and G4
(n = 2). Between doses 2 and 3, the distribution of the rotavirus serotypes in the total number (n = 34) of RVGE-related health care encounters in Analysis B, which also includes the 22 health care encounters in Analysis A, among vaccine recipients was G1 (n = 3) and among placebo recipients was G1
(n = 31) and G3 (n = 3). cAnalysis A: ≥14 days post dose 1 (PD1) up to dose 2 and ≥14 days PD2 up to dose 3. dAnalysis B: ≥14 days PD1 through 13 days
PD2 and from ≥14 days PD2 through 13 days PD3.
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Results

Efficacy between doses against health care encounters attributable to G1–G4 RVGE in infants who received all 3 doses. In
Analysis A, the reduction in the rate of combined hospitalizations and ED visits for G1–G4 RVGE between doses 1 and 2
was 100% (95% CI: 72–100%) and between doses 2 and 3 was
91% (95% CI: 63–99%) (Table 1). There were only 2 RVGEassociated health care encounters among vaccine recipients, and
both encounters were ED visits that occurred between doses 2
and 3. In contrast, there were 37 RVGE-associated health care
encounters among placebo recipients: 15 between doses 1 and
2 and 22 between doses 2 and 3. Sixteen of the 37 health care
encounters were hospitalizations. Although Analysis B extended
the follow-up interval, the reduction in the rate of combined hospitalizations and ED visits for G1–G4 RVGE was identical to that
of Analysis A [100% between doses 1 and 2 and 91% between
doses 2 and 3, with small changes to the CIs (Table 1)]. Only
1 additional RVGE-associated health care encounter, an ED
visit between doses 2 and 3, was observed in the vaccine group,
whereas 26 additional encounters were observed in the placebo
group, 14 between doses 1 and 2 and 12 between doses 2 and 3.
Under both analysis strategies, vaccine efficacy against G1–G4
RVGE hospitalizations was 100% between doses. Overall, G1
was the most common serotype identified (detailed breakdown
provided in footnote, Table 1).
Efficacy between doses against health care encounters
attributable to RVGE regardless of serotype in infants who
received all 3 doses. In Analysis A, the reduction in the rate of
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combined hospitalizations and ED visits due to RVGE regardless
of serotype was 82% (95% CI: 39–97%) between doses 1 and 2
and 84% (95% CI: 54–96%) between doses 2 and 3 (Table 2).
Among vaccine recipients, there were 7 health care encounters,
3 between doses 1 and 2 and 4 between doses 2 and 3; 1 of the
health care encounters was a hospitalization. Among placebo
recipients, there were 42 health care encounters, 17 between
doses 1 and 2 and 25 between doses 2 and 3; 18 of the 42 health
care encounters were hospitalizations. The reduction in the rate
of combined hospitalizations and ED visits was slightly greater
in Analysis B (Table 2). Two additional RVGE-related health
care encounters among the vaccine recipients (1 between doses 1
and 2 and 1 between doses 2 and 3) and 31 among the placebo
recipients (15 between doses 1 and 2 and 16 between doses 2
and 3) were captured in Analysis B. Among the vaccine recipients, none of the additional health care encounters were hospitalizations. Among placebo recipients, 16 of the 31 additional health
care encounters were hospitalizations. Overall, vaccine efficacy
against RVGE hospitalizations between doses ranged from 90%
to 100%. G1 was the most common serotype identified (detailed
breakdown provided in footnote, Table 2).
Efficacy of RV5 against RVGE-related health care encounters among the subset of infants who received less than 3 doses
(incomplete regimen). Subject compliance in REST was high,
with 59,210 infants (86%) having received 3 doses of RV5 or placebo.2 In REST, among infants who received only 1 dose or only
2 doses, the number of health care encounters was small, and the
rate reductions in RVGE-associated combined hospitalizations
and ED visits were not statistically significant.
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Table 2. Rate reduction in RVGE-related health care encounters (hospitalizations and ED visits) between vaccine dosesa attributable to rotavirus
of any serotype
RVGE of any
serotypeb

Interval (N)

Health care encounter

Vaccine

Placebo

Efficacy (%)

95% CI (%)

Counts (n)/evaluable (n)
Analysis A

c

Doses 1 to 2 (58,856)

Doses 2 to 3 (59,064)

Analysis Bd

Doses 1 to 2 (58,858)

Doses 2 to 3 (59,033)

Hospitalizations

0/29,422

8/29,434

100

42–100

ED visits

3/29,422

9/29,434

67

<0–94*

Combined hospital and ED visits

3/29,422

17/29,434

82

39–97

Hospitalizations

1/29,497

10/29,567

90

30–100

ED visits

3/29,497

15/29,567

80

29–96

Combined hospital and ED visits

4/29,497

25/29,567

84

54–96

Hospitalizations

0/29,420

15/29,438

100

72–100

ED visits

4/29,420

17/29,438

76

28–94

Combined hospital and ED visits

4/29,420

32/29,438

88

65–97

Hospitalizations

1/29,484

19/29,549

95

67–100

ED visits

4/29,484

22/29,549

82

46–95

Combined hospital and ED visits

5/29,484

41/29,549

88

69–96
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N, number of evaluable infants who received 3 doses of vaccine or placebo; RVGE, rotavirus gastroenteritis; CI, confidence interval; ED, emergency
department. *Not statistically significant. aGiven that the interval between doses was to be 4–10 weeks, the range of follow up was 14–56 days per
infant in Analysis A and 14–69 days per infant in Analysis B. bIn addition to rotavirus serotypes G1 to G4, between doses 1 and 2, 4 nontypeable and
3 G9 RVGE-related health care encounters were detected among vaccine and placebo recipients, respectively. Between doses 2 and 3, G9 (n = 3), G8
(n = 1), G10 (n = 1), and nontypeable (n = 2) RVGE-related health care encounters were also detected among placebo recipients, whereas 2 additional
nontypeable RVGE-related health care encounters were detected among vaccine recipients. cAnalysis A: ≥14 days post dose 1 (PD1) up to dose 2 and
≥14 days PD2 up to dose 3. dAnalysis B: ≥14 days PD1 through 13 days PD2 and from ≥14 days PD2 through 13 days PD3.

Among infants who received only 1 dose of RV5/placebo,
the number of health care encounters was small for the G1–G4
RVGE analysis (RV5, 3 G1-related events; placebo, 6 G1-related
events) and the RVGE of any serotype analysis [RV5, 6 events
(3 G1-related, 1 G9-related and 2 nontypeable); placebo, 7 events
(6 G1-related and 1 nontypeable)]. Among the 5,408 evaluable
infants who received only 1 dose (2,738 in the RV5 group and
2,670 in the placebo group), the rate reduction in combined hospitalizations and ED visits for G1–G4 RVGE was 52% (95% CI:
<0–92%). The rate reduction in combined hospitalizations and
ED visits for RVGE of any serotype among the 5,409 evaluable
infants who received only 1 dose (2,738 in the RV5 group and
2,671 in the placebo group) was 18% (95% CI: <0–75%).
Similarly, among infants who received only 2 doses of RV5/
placebo, the number of health care encounters was also small for
the G1–G4 RVGE analysis (RV5, 1 G3-related event; placebo,
3 G1-related events) and the RVGE of any serotype analysis
[RV5, 1 G3-related event; placebo, 4 events (3 G1-related and
1 G9-related)]. Among the 2,457 evaluable infants who received
only 2 doses (1,202 in the RV5 group and 1,255 in the placebo
group), the rate reduction in combined hospitalizations and ED
visits for G1–G4 RVGE was 64% (95% CI: <0–99%), whereas
the rate reduction in combined hospitalizations and ED visits for
RVGE of any serotype among the 2,456 evaluable infants who
received only 2 doses (1,202 in the RV5 group and 1,254 in the
placebo group) was 73% (95% CI: <0–100%).

www.landesbioscience.com

Discussion

In REST, both the safety and efficacy of the complete regimen of
RV5 were demonstrated in nearly 70,000 infants.2 The prespecified time frame to measure the efficacy of RV5 in reducing the
rate of RVGE-associated health care encounters (i.e., hospitalizations and ED visits) in REST started 14 days after completion of
the 3-dose regimen. Given that many infants are routinely vaccinated during the season when rotavirus is circulating and risk
of illness is greatest, post-hoc analyses were conducted to evaluate the efficacy of RV5 before completion of the 3-dose regimen.
Although REST was not designed or powered to examine the
efficacy between doses, vaccine efficacy between doses among
infants who ultimately completed the 3-dose vaccination schedule was retrospectively examined. A separate analysis among the
small number of infants who received only 1 dose or only 2 doses
of vaccine in REST also was conducted.
In the post-hoc analyses of infants who completed the 3-dose
regimen, a high level of protection against RVGE-related hospitalizations and ED visits combined caused by serotypes G1–G4
and rotavirus of any serotype between doses was demonstrated
by RV5. Vaccine efficacy against G1–G4 RVGE-related hospitalizations and ED visits was 100% between doses 1 and 2 and
91% between doses 2 and 3 regardless of whether the analysis
time frame ended at the subsequent dose or 13 days after the subsequent dose. Similarly, vaccine efficacy against hospitalizations
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and ED visits for RVGE of any serotype was 82% to 88%
between doses 1 and 2 and 84% to 88% between doses 2 and 3.
Based on the vaccine schedule, these data suggest the potential
for RV5 to provide high efficacy and rapid protection in young
infants during the immunization schedule. Between doses, vaccine efficacy against hospitalizations alone was 100% for G1–G4
RVGE and 90% to 100% for RVGE caused by any serotype.
These results may be of interest because rotavirus-related health
care encounters can occur in young infants. In the era before universal vacccination in the US, 17% of rotavirus hospitalizations
occurred in infants less than 6 months of age.4 Circumstances in
Europe may be similar to those in the US,5 although variation
among European countries exists.6,7
The efficacy between doses of RV1, whose complete vaccine
regimen consists of 2 doses, against RVGE was evaluated in a
European Phase III study that enrolled over 4,000 infants. From
the day of dose 1 up until dose 2, vaccine efficacy was 100% (95%
CI: <0–100%) against severe RVGE and 90% (95% CI: 9–100%)
against RVGE of any severity.8,9 In a larger Phase III study that
enrolled infants from Latin America and Finland, the efficacy of
RV1 against severe RVGE in the Latin American cohort was 51%
between doses 1 and 2 and 61% from dose 1 until 14 days after
dose 2, with wide CIs given the small number of cases.9 Because
the trials for the two vaccines were conducted differently, the
results between the trials can not be directly compared.
With respect to infants who received only 1 dose or only
2 doses of RV5 or placebo, the number of RVGE-related health
care encounters observed was small. Although the estimates were
positive, the efficacy was not statistically significant in either evaluation. However, higher protection against RVGE-attributable
health care encounters was generally provided by 2 doses than
by only 1 dose.
The efficacy against RVGE cases of any severity, which was
measured in the clinical efficacy substudy of REST, was analyzed
in a similar manner as the efficacy between doses and after only 1
dose or only 2 doses against RVGE-related health care encounters.
The cohort in the clinical efficacy substudy was less than one-tenth
the entire size of REST and the efficacy outcomes in these evaluations were generally not statistically significant (data not shown).
Although some protection is likely conferred with less than
3 doses of RV5, only the complete 3-dose vaccine series was
prospectively studied in Phase III trials and may provide more
durable and optimal protection. Because REST was not designed
to evaluate the efficacy of RV5 with less than 3 doses, conclusions
drawn from these analyses should be interpreted cautiously.
However, the effectiveness of partial vaccination with RV5 has
been evaluated since licensure in routine clinical use in the US.10
Fecal specimens from children with acute gastroenteritis 15 days
to 23 months of age were collected over a 5-month period. One,
2 and 3 doses of RV5, respectively, were 69% (95% CI: 13–89%),
81% (95% CI: 13–96%) and 88% (95% CI: 68–96%) effective
at preventing ED visits or hospitalizations from rotavirus disease
when children with acute respiratory infection and rotavirus negative gastroenteritis were used as the combined control group.10
Similar findings were observed by the New Vaccine Surveillance
Network, a program coordinated by the US Centers for Disease

Control and Prevention designed to evaluate the impact of new
vaccines at several sites in the US.11 Based upon data from the
2007 and 2008 rotavirus seasons, their results showed that 1, 2
and 3 doses of RV5 were 71% (95% CI: 17–90%), 72% (95%
CI: 1–92%) and 88% (95% CI: 47–97%), respectively, effective at preventing RVGE-related ED visits and hospitalizations. A
consistent pattern of reduction of all-cause and rotavirus-related
gastroenteritis has been repeatedly observed after introduction of
RV5. These significant reductions have been observed in other
postlicensure disease surveillance and effectiveness studies in the
US12-14 and other countries that have introduced RV5 into their
childhood immunization schedules.14-19
Conclusions. RV5 is a 3-dose vaccine that protects infants
against RVGE. RV5 provided a high level of protection between
doses against hospitalizations and ED visits for RVGE starting
as early as 14 days after the first dose. This may be particularly
beneficial to infants being immunized during, or just prior to, the
rotavirus season.
Patients and Methods
Study design. REST was a large-scale, placebo-controlled, multicenter, randomized clinical trial that enrolled nearly 70,000
infants year round.2,3,20 Healthy infants between 6 and 12 weeks
of age at dose 1 were randomized 1:1 to receive 3 oral doses of
RV5 or placebo as outlined in Figure 1A.
Post-hoc analyses. Efficacy between doses of RV5, as measured
by a reduction in the rate of RVGE-related health care encounters, including hospitalizations and ED visits, among infants who
received all 3 doses of RV5 or placebo was evaluated to examine
whether the vaccine confers early protection before completion of
the 3-dose regimen (Fig. 1B). The efficacy of RV5 for infants who
received only 1 dose or only 2 doses of vaccine or placebo was also
evaluated (Fig. 1B). RVGE was defined exactly as it was in REST.2
Reverse transcription polymerase chain reaction and sequencing
was used to genotype all rotavirus-positive stool samples.2 In REST,
the per-protocol measures of efficacy were assessed beginning 14
days post-dose (PD) 3 to allow time for an immune response to the
last dose to develop (Fig. 1A) and a consistent approach was used
for the between-dose and less-than-3-dose analyses.
Among infants who completed the 3-dose vaccination series
and were not protocol violators (i.e., per-protocol population), vaccine efficacy between doses was measured using 2 analyses that differed with regard to the time interval used: (1) Analysis A, defined
as ≥14 days PD1 up to dose 2 and ≥14 days PD2 up to dose 3; and
(2) Analysis B, defined as ≥14 days PD1 through 13 days PD2 and
from ≥14 days PD2 through 13 days PD3 (Fig. 1B). In both analyses, 14 days PD1 or PD2 was used as the starting point to allow time
for an immune response to develop, consistent with the time frame
used to evaluate the per-protocol efficacy of the vaccine.2 However,
in Analysis B, the analysis interval extended 13 days beyond the
next dose to capture any RVGE-related events occurring before
the effect of an immune response to the subsequent dose might be
expected. The interval between doses was to be 4 to 10 weeks, and
the follow-up times for the analyses of efficacy started and ended at
the indicated time intervals (Fig. 1B). In addition, vaccine efficacy
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Figure 1. Overview of REST and the post-hoc analyses performed. (A) In REST, the first dose was given at 6 to 12 weeks of age, the last dose was given
no later than 32 weeks of age, and the interval between doses was 4 to 10 weeks. The main measures of efficacy were assessed beginning 14 days
PD3. (B) Post-hoc analyses of RV5 efficacy between doses and with less than 3 doses. All analyses of efficacy began 14 days after the receipt of a dose
(indicated by the dark circles). REST, Rotavirus Efficacy and Safety Trial.

of only 1 dose or only 2 doses of RV5 was measured beginning
14 days after the receipt of the last dose among infants who did not
complete the 3-dose regimen, but who were not otherwise protocol violators (Fig. 1B). For all analyses, infants were followed for
2 years after vaccination and efficacy against G1–G4 (i.e., human
G serotypes contained in the vaccine) RVGE and RVGE of any
serotype were determined.
Statistical analysis. The exact binomial method for ratios of
Poisson counts was used to evaluate the rate reduction for rotavirus-related hospitalizations and ED visits in the vaccine group
compared with the placebo group.21 This approach was the same

www.landesbioscience.com

as the analysis technique used in REST,2 with the exception that
exact methodology was used rather than the generalized estimating equations (GEE), because GEE is not optimal in small
samples.
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